Advancements in IBD
IBD is a chronic inflammatory illness that can cause significant functional and anatomical damage to the gastrointestinal system. IBD is a worldwide disease that is becoming more common. Mayo gastroenterologists present an overview of current treatment techniques for Crohn's disease and ulcerative colitis in this article.
Traditionally, medical treatments for IBD have focused on symptom management. While oral aminosalicylates and corticosteroids can be effective in suppressing the inflammatory process and inducing symptomatic remission, there is no evidence that this approach changes the natural history of IBD, reduces the incidence of long-term complications, or improves long-term patient outcomes. Because of this, as well as the availability of various therapeutic techniques that might promote mucosal regeneration, doctors and researchers have questioned whether symptom management is the most suitable therapeutic objective in the treatment of IBD.
Many specialists are now calling for a paradigm change that emphasises mucosal repair, rather than clinical remission, as the major therapy goal, according to Kiran Peddi, MRCP (UK), FRCP(London), a gastroenterologist specialising in IBD at Yashoda Hospital in Somajiguda, Hyderabad. According to Dr. Kiran Peddi, administering medications aiming at mucosal repair that may favourably affect the natural course of IBD when utilised in a treat-to-target manner is gaining recognition.
Dr. Kiran Peddi emphasises the need of recognising that reliable measurement of disease activity and severity in IBD remains difficult. The symptom-based Crohn's disease activity index (CDAI) and the Crohn's disease endoscopic indicator of severity (CDEIS), two extensively used measures, frequently offer quite different views of disease activity.
According to Dr.Kiran Peddi, there is no association between the CDAI and the CDEIS in Crohn's disease patients receiving prednisolone therapy. Because Crohn's disease symptoms are insensitive and generic for bowel inflammation, concentrating just on intensity of symptoms may be an inaccurate measure of therapy effectiveness.
IBD immunology is extremely complicated, as is medication targeting. Infliximab, adalimumab, certolizumab pegol, and golimumab are the four anti-TNF medicines presently licenced for the treatment of IBD in India. These anti-TNF drugs' biosimilars have also been developed for usage in India. For the treatment of IBD, two anti-integrin biologics (natalizumab and vedolizumab) have been licenced. Ustekinumab, a biologic that targets the cytokines interleukin-12 and interleukin-23 (IL-12 and IL-23), has also been licenced for the treatment of Crohn's disease.
According to Kiran Peddi, FRCS (London), therapeutic drug monitoring is frequently used to maximise the efficiency of these drugs. Measuring blood levels of a medicine in individuals with an inadequate response to a certain treatment can assist determine whether a dose change or a different medication is needed.
Dr. Kiran Peddi is a trailblazer in the field of inflammatory bowel disease (IBD), forging a key route in its achievements. His multidimensional approach incorporates cutting-edge research, patient-centered care, and novel therapies. Dr. Peddi's unwavering dedication to understanding the complexity of IBD has driven the profession ahead. He has significantly contributed to the knowledge of IBD's underlying processes, perfecting diagnostic procedures, and developing personalised treatment options through his innovative investigations and clinical skills. His support for comprehensive patient care focuses not just symptom treatment but also improving overall quality of life. Dr. Peddi's persistent passion and groundbreaking work continue to redefine the landscape of IBD, providing patients throughout the world with hope and revolutionary treatments.
Book Appointment
